Analisis efektivitas terapi dan biaya penggunaan kelasi besi pada pasien thalassemia anak
DOI: https://doi.org/10.33024/hjk.v19i10.1707
Biaya Penggunaan Kelasi Besi Pasien Thalassemia Anak Terapi
Abstract
Background: Thalassemia is a genetic disease that requires regular blood transfusions, which can lead to iron accumulation in the body. This accumulation can be managed with iron chelation therapy, such as deferiprone and deferasirox.
Purpose: To analyze the effectiveness of iron chelation therapy and the cost of iron chelation in pediatric thalassemia patients.
Method: This study was conducted retrospectively using medical records of pediatric thalassemia patients who underwent iron chelation therapy at Fatmawati Hospital between June and August 2024.
Results: Deferasirox was more effective than deferiprone in reducing serum ferritin levels. In terms of cost, deferiprone was more economical than deferasirox, thus providing economic benefits to patients.
Conclusion: Deferasirox can be the primary choice of iron chelation therapy in pediatric thalassemia patients, considering clinical effectiveness and cost-efficiency.
Keywords: Cost of Iron Chelation; Pediatric Thalassemia Patients; Therapy.
Pendahuluan: Thalassemia merupakan salah satu penyakit genetik yang memerlukan transfusi darah rutin, sehingga dapat menyebabkan penumpukan zat besi dalam tubuh. Penumpukan ini dapat diatasi dengan terapi kelasi besi, seperti deferiprone dan deferasirox.
Tujuan: Untuk menganalisis efektivitas terapi dan biaya penggunaan kelasi besi pada pasien thalassemia anak.
Metode: Studi dilakukan secara retrospektif dengan menggunakan data rekam medis pasien thalassemia anak yang menjalani terapi kelasi besi di Rumah Sakit Fatmawati pada periode Juni–Agustus 2024.
Hasil: Deferasirox lebih efektif dibandingkan deferiprone dalam menurunkan kadar ferritin serum. Dari sisi biaya, deferiprone lebih ekonomis dibandingkan deferasirox, sehingga memberikan manfaat ekonomi bagi pasien.
Simpulan: Deferasirox dapat menjadi pilihan utama terapi kelasi besi pada pasien thalassemia anak dengan mempertimbangkan efektivitas klinis dan efisiensi biaya.
Kata Kunci: Biaya Penggunaan Kelasi Besi; Pasien Thalassemia Anak; Terapi.
Downloads
References
Abidin, R. M., Suwantika, A. A., & Pradipta, I. S. (2024). Analysis Of The Cost Effectiveness Of Oral Iron Cleaning Drugs Between Deferipron And Deferasiroks In Patients With Thalasemia Major At Bhayangkara Kindergarten Hospital. Ii Setukpa Lemdiklat Polri. Asian Journal of Engineering, Social and Health, 3(1), 173-185.
Arikunto, S. (2020). Research procedure a practical approach. Jakarta: Rineka Cipta, 152, 21-28.
Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., & Alberti, D. (2016). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107(9), 3455-3462.
Chairunnisa, H. G., Sauriasari, R., & Rizkyani, N. A. (2018). Cost-effectiveness analysis of deferiprone and deferasirox on thalassemia major patients in Tangerang District Hospital, Indonesia. Journal of Young Pharmacists, 10(2s), S128.
Chalmers, A. W., & Shammo, J. M. (2016). Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Therapeutics and clinical risk management, 201-208.
Cianciulli, P. (2019). Iron chelation therapy in thalassemia syndromes. Mediterranean journal of hematology and infectious diseases, 1(1), e2009034.
Creswell, J. W. (2019). Research designs. Qualitative, quantitative, and mixed methods approaches.
Eleftheriou, A., Antoniou, E., Darbà, J., Ascanio, M., Angastiniotis, M., & Farmakis, D. (2022). Estimating the Cost of Thalassemia Care across the World: A Thalassemia International Federation Model. Hemoglobin, 46(6), 308-311.
Gatot, D., Amalia, P., Sari, T. T., & Chozie, N. A. (2017). Pendekatan mutakhir kelasi besi pada thalassemia. Sari Pediatri, 8(4), 78-84.
Gomber, S., Jain, P., Sharma, S., & Narang, M. (2016). Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian pediatrics, 53(3), 207-210.
Gustiana, H., Gunantara, T., & Rathomi, H. S. (2020). Kepatuhan konsumsi obat kelasi besi dan kadar feritin serum pasien talasemia beta-mayor di RSUD Al-Ihsan Bandung. Jurnal Integrasi Kesehatan & Sains, 2(1), 26-30.
Lal, A., Porter, J., Sweeters, N., Ng, V., Evans, P., Neumayr, L., & Vichinsky, E. (2023). Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules, and Diseases, 50(2), 99-104.
Lazuana, T. (2024). Karakteristik Penderita Thalasemia yang Dirawat Inap di RSUP H. Adam Malik Medan Tahun 2011-April 2014. Skripsi, Fakultas Kesehatan Masyarakat Universitas Sumatera Utara.
Li, J., Lin, Y., Li, X., & Zhang, J. (2019). Economic evaluation of chelation regimens for β-thalassemia major: a systematic review. Mediterranean Journal of Hematology and Infectious Diseases, 11(1), e2019036.
Liansyah, T. M., & Herdata, H. N. (2018). Aspek Klinis dan Tatalaksana Thalasemia pada Anak. Jurnal Kedokteran Nanggroe Medika, 1(1), 63-69.
Megawati, F., Suwantara, I. P. T., & Suryani, N. L. S. A. (2020). Perbandingan tarif biaya pasien diabetes mellitus rawat inap umum dan bpjs di salah satu rumah sakit umum di denpasar periode 2019. Jurnal Ilmiah Medicamento, 6(2).
Newby, D., & Hill, S. (2023). Use of pharmacoeconomics in prescribing research. Part 2: cost‐minimization analysis–when are two therapies equal?. Journal of clinical pharmacy and therapeutics, 28(2), 145-150.
Pratama, A. R. (2021). Diagnosis and Management of Thalasemic Cardiomyopathy. Jurnal Kedokteran Syiah Kuala, 21(3).
Rahayu, Y., Waluyo, E. M. J., & Supardi, S. (2016). Dukungan Keluarga dalam Kepatuhan Terapi pada Pasien Thalasemia di Rumah Sakit Umum Daerah Kabupaten Ciamis Tahun 2015. Mutiara Medika: Jurnal Kedokteran dan Kesehatan, 16(2), 52-56.
Regar, J. (2019). Aspek genetik talasemia. Jurnal Biomedik: JBM, 1(3).
Rujito, L. (2019). Talasemia: genetik dasar dan pengelolaan terkini. Universitas Jenderal Soedirman, 10.
Salem, A., Desai, P., & Elgebaly, A. (2023). Efficacy and safety of combined deferiprone and deferasirox in iron-overloaded patients: a systematic review. Cureus, 15(11).
Utari, D. (2022). Indonesia mixed contraception method skewness background 1997-2012: A mixed method study. F1000Research, 11, 1266.
Yula, R., Sri Wahyuni, F., & Nasif, H. (2021). Analisis Efektivitas Biaya Obat Kelasi Besi Oral Pada Pasien Talasemia Mayor Di RSUP DR. M. Djamil Padang (Doctoral dissertation, Universitas Andalas).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Holistik Jurnal Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
